Kronos Worldwide Inc Reports Q3 2024 GAAP EPS of 0. ...
KRON Stock | USD 1.03 0.01 0.98% |
About 50% of Kronos Bio's investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Kronos Bio suggests that some traders are interested. Kronos Bio's investing sentiment overview a quick insight into current market opportunities from investing in Kronos Bio. Many technical investors use Kronos Bio stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Kronos |
Net Income Achieved 71.8 million in Q3 2024, a significant turnaround from a net loss of 20.4 million in Q3 2023, driven by higher sales and production volu
Read at gurufocus.com
Kronos Bio Fundamental Analysis
We analyze Kronos Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kronos Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kronos Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
Kronos Bio is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Kronos Bio Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kronos Bio stock to make a market-neutral strategy. Peer analysis of Kronos Bio could also be used in its relative valuation, which is a method of valuing Kronos Bio by comparing valuation metrics with similar companies.
Peers
Kronos Bio Related Equities
INBX | Inhibrx | 10.07 | ||||
CTMX | CytomX Therapeutics | 7.32 | ||||
LRMR | Larimar Therapeutics | 6.61 | ||||
NVCT | Nuvectis Pharma | 5.81 | ||||
GOSS | Gossamer Bio | 4.35 | ||||
ASMB | Assembly Biosciences | 4.11 | ||||
CCCC | C4 Therapeutics | 2.51 | ||||
CRNX | Crinetics Pharmaceuticals | 2.23 | ||||
ERAS | Erasca | 2.17 | ||||
MRUS | Merus BV | 0.19 | ||||
ACHL | Achilles Therapeutics | 0.88 | ||||
SPRO | Spero Therapeutics | 1.15 | ||||
NXTC | NextCure | 1.23 | ||||
EWTX | Edgewise Therapeutics | 1.48 | ||||
REPL | Replimune | 3.20 | ||||
LYEL | Lyell Immunopharma | 4.92 | ||||
LYRA | Lyra Therapeutics | 5.26 | ||||
GBIO | Generation Bio | 5.81 |
Check out Kronos Bio Hype Analysis, Kronos Bio Correlation and Kronos Bio Performance. To learn how to invest in Kronos Stock, please use our How to Invest in Kronos Bio guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kronos Bio. If investors know Kronos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kronos Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Kronos Bio is measured differently than its book value, which is the value of Kronos that is recorded on the company's balance sheet. Investors also form their own opinion of Kronos Bio's value that differs from its market value or its book value, called intrinsic value, which is Kronos Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kronos Bio's market value can be influenced by many factors that don't directly affect Kronos Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kronos Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kronos Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kronos Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.